CENTER FOR DRUG EVALUATION AND RESEARCH

APPROVAL PACKAGE FOR:

APPLICATION NUMBER

20-449/S-028

Chemistry Review(s)

CHEMIST'S REVIEW

1. ORGANIZATION	2. NDA NUMBER
HFD-150 DODP	20-449

3. NAME AND ADDRESS OF APPLICANT *(City and State)*

Aventis Pharmaceuticals, Inc.
200 Crossing Boulevard
P.O. Box 6890
Bridgewater, NJ 08807-0890
Attention: Cheryl Anderson
Senior Director and Oncology Therapeutic Area Head
Telephone: (908)-394-6471

4. AF NUMBER

5. SUPPLEMENT (S)
NUMBER(S) DATES(S)

6. NAME OF DRUG	7. NONPROPRIETARY NAME	SE1-028	26-Jan-04
Taxotere	docetaxel		

8. SUPPLEMENT PROVIDES FOR:

a claim of categorical exclusion from the Environmental Assessment to support the use of Taxotere in combination with prednisone for the treatment of patients with androgen independent metastatic prostate cancer and related labeling changes

9. AMENDMENTS DATES

BZ 29-Mar-04

10. PHARMACOLOGICAL CATEGORY	11. HOW DISPENSED	12. RELATED IND/NDA/DMF
antineoplastic	RX X OTC ____	
13. DOSAGE FORM(S)	**14. POTENCY**	
Injection Concentrate	20 mg and 80 mg	

15. CHEMICAL NAME AND STRUCTURE

16. RECORDS AND REPORTS
CURRENT YES___ NO___
REVIEWED YES___ NO___

17. COMMENTS

See page 2

cc:
NDA 20-449
HFD-150/Div. File
HFD-150/RWood
HFD-150/YAHsieh
HFD-150/AStaten
R/D Init. by:

18. CONCLUSIONS AND RECOMMENDATIONS

It is recommended that the request for a claim of categorical exclusion for an Environmental Assessment should be approved. The proposed labeling revisions are acceptable from a CMC view point.

19. REVIEWER

NAME	SIGNATURE	DATE COMPLETED
Yung-Ao Hsieh, Ph.D.		15-Apr-04

DISTRIBUTION ORIGINAL JACKET x DIVISION FILE x REVIEWER x CSO x SUP. CHEMIST x

Summary of the Application
Taxotere for Injection was approved on May 14, 1996 for the treatment of patients with locally advanced or metastatic breast cancer who have progressed or relapsed during anthracycline based therapy. Its indication has been gradually expanded, since. This efficacy supplement provides for the use of Taxotere® (docetaxel) for Injection Concentrate (20 mg and 80 mg) in combination with prednisone for the treatment of patients with androgen independent metastatic prostate cancer. The proposed dosing regimen is TAXOTERE* 75 mg/m^2 IV every 3 weeks and prednisone 5 mg PO BID. In support of this submission, the applicant has submitted a claim of categorical exclusion under 21 CFR Part 25.31(b).

The applicant certifies that the expected level of docetaxel introduced into the environment, as the result of the approval of this efficacy supplemental application and the previous approval, will not exceed a concentration of 1 ppb at the point of entry into the aquatic environment.

[ ]

Labeling Revision
The proposed package insert revisions (Section 1.5.1 Proposed Labeling Text) are acceptable from a CMC viewpoint.

Conclusion and Recommendation
Adequate information has been presented to show that the requested approval of the efficacy supplement NDA 20-449 SE1-028 qualifies for a categorical exclusion from the requirement to prepare an EA under 21 CFR 25.31(b). It is recommended that the claim for a categorical exclusion for an EA should be approved.

cc:
NDA 20-449
HFD-150/Div. File
HFD-150/RHWood
HFD-150/YAHsieh
HFD-150/AStaten

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Yung-Ao Hsieh
4/19/04 01:37:30 PM
CHEMIST

Rebecca Wood
4/19/04 01:49:53 PM
CHEMIST